Lung Adenocarcinoma Clinical Trial
Official title:
Deep Learning Signature Based on Whole Slide Images for Predicting the Novel Grading System of Resected Lung Adenocarcinoma
NCT number | NCT05925764 |
Other study ID # | WSIGS |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | May 1, 2023 |
Est. completion date | October 31, 2023 |
Verified date | June 2023 |
Source | Shanghai Pulmonary Hospital, Shanghai, China |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The purpose of this study is to evaluate the performance of a whole slide image based deep learning signature for predicting the novel grading system in resected lung adenocarcinoma based on a multicenter prospective cohort.
Status | Recruiting |
Enrollment | 800 |
Est. completion date | October 31, 2023 |
Est. primary completion date | October 31, 2023 |
Accepts healthy volunteers | |
Gender | All |
Age group | 20 Years to 75 Years |
Eligibility | Inclusion Criteria: 1. Pathological confirmation of primary lung adenocarcinoma; 2. Age ranging from 20-75 years; 3. Obtained written informed consent. Exclusion Criteria: 1. Multiple lung lesions; 2. Poor quality of whole slide images; 3. Participants with incomplete clinical information; 4. Mucinous adenocarcinomas and variants; 5. Participants who have received neoadjuvant therapy. |
Country | Name | City | State |
---|---|---|---|
China | The First Affiliated Hospital of Nanchang University | Nanchang | Jiangxi |
China | Ningbo HwaMei Hospital | Ningbo | Zhejiang |
China | Affiliated Hospital of Zunyi Medical University | Zunyi | Guizhou |
Lead Sponsor | Collaborator |
---|---|
Shanghai Pulmonary Hospital, Shanghai, China | Ningbo HwaMei Hospital, Zhejiang, China, The First Affiliated Hospital of Nanchang University, Jiangxi, China, Zunyi Medical College |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Specificity | The specificity of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 | |
Other | Positive predictive value | The positive predictive value of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 | |
Other | Negative predictive value | The negative predictive value of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 | |
Other | Accuracy | The accuracy of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 | |
Primary | Area under the receiver operating characteristic curve | The area under the receiver operating characteristic curve of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 | |
Secondary | Sensitivity | The sensitivity of the deep learning model based on whole slide imge in predicting the novel grading system of resected lung adenocarcinoma. The novel grading system of lung adenocarcinoma includes grade I, grade II, and grade III. And the model will output the predictive values (grade I/grade II/grade III) of the grade for each patient with resected lung adenocarcinoma. | 2023.5.1-2023.10.31 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT02898857 -
Chemoresistance and Involvement of the NOTCH Pathway in Patients With Lung Adenocarcinoma
|
N/A | |
Completed |
NCT02127359 -
Whole-Exome Sequencing (WES) of Cancer Patients
|
||
Recruiting |
NCT01249066 -
Expression of AMP-activated Protein Kinase (AMPK) Protein in Lung Adenocarcinoma
|
N/A | |
Not yet recruiting |
NCT04482829 -
TCM in the Treatment of Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04929041 -
Testing the Addition of Radiation Therapy to Immunotherapy for Stage IV Non-Small Cell Lung Cancer Patients Who Are PD-L1 Negative
|
Phase 2/Phase 3 | |
Terminated |
NCT04691375 -
A Study of PY314 in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT02621333 -
Chemotherapy Combined Autologous Cytokine-induced Killer Cells in Naive Stage IV EGFR-wild Type Lung Adenocarcinoma
|
Phase 2 | |
Active, not recruiting |
NCT02282267 -
Blood Detection of EGFR Mutation For Iressa Treatment
|
N/A | |
Not yet recruiting |
NCT01942629 -
Prognostic Value of the Marker P63 in Adenocarcinoma of Lung, Breast, and Pancreas
|
N/A | |
Recruiting |
NCT01482585 -
Study of Early-stage Lung Adenocarcinoma for Early Detection and Effective Treatment Strategy
|
N/A | |
Recruiting |
NCT03376737 -
Study of Apatinib as the Maintenance Therapy in Advanced Lung Adenocarcinoma
|
Phase 2 | |
Recruiting |
NCT05537922 -
I3LUNG: Integrative Science, Intelligent Data Platform for Individualized LUNG Cancer Care With Immunotherapy
|
||
Recruiting |
NCT04937283 -
Segmentectomy Versus Lobectomy for Lung Adenocarcinoma ≤ 2cm
|
N/A | |
Recruiting |
NCT06255197 -
Characteristics, Treatment Patterns and Outcomes for Patients With Surgically Resected Lung Cancers
|
||
Completed |
NCT02093000 -
A Study Examining Maintenance Bevacizumab (Avastin®) Monotherapy in Participants With Advanced Lung Adenocarcinoma
|
N/A | |
Recruiting |
NCT04119024 -
Gene Modified Immune Cells (IL13Ralpha2 CAR T Cells) After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors
|
Phase 1 | |
Terminated |
NCT04682431 -
A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05736991 -
Deep Learning Signature for Predicting the Novel Grading System of Clinical Stage I Lung Adenocarcinoma
|
||
Enrolling by invitation |
NCT05136014 -
Evaluation of the Response to Tyrosine Kinase Inhibitors in Localized Non-small Cell Lung Cancer (NSCLC) Patients With EGFR Mutation in a Patient-derived Organoid Model
|
||
Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 |